Market Analysis and Insights: Global Follicular Lymphoma Drugs Market
Follicular lymphoma is a cancer that affects white blood cells called lymphocytes. There are two types of lymphomas: Hodgkin's and non-Hodgkin's, based on the kind of white blood cell they affect. Follicular lymphoma is a non-Hodgkin's lymphoma.Drugs for Follicular lymphoma are Anti-CD20 mAbs, Chemotherapy Agents, Kinase Inhibitor, etc.
The global Follicular Lymphoma Drugs market size is projected to reach US$ 2836.9 million by 2028, from US$ 1711.1 million in 2021, at a CAGR of 7.4% during 2022-2028.
Global core follicular lymphoma drugs players include Roche, Teva and Bayer etc. The Top3 companies hold a share about 57%. North America is the largest market, with a share about 58%, followed by Europe and Asia Pacific with the share about 21% and 20%.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Follicular Lymphoma Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Follicular Lymphoma Drugs market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Follicular Lymphoma Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Follicular Lymphoma Drugs market.
Impact of Covid-19 Outbreak
This section of the report has explored the overall status of the Covid scenario and has offered valuable insights into the changes in supply chain disruption, fluctuations in demand, etc. The analysts have also focused on the key measures that the companies are opting to withstand the harsh scenario.
Segmental Analysis
The report has been segmented into product and application segments. The researchers have documented all the products present today in the Follicular Lymphoma Drugs market. They have also shed light on the new product innovations and launches by the key players. In the segmental analysis, the analysts have provided revenue forecast figures based on type and application for the period 2017-2028. They have also discussed about the growth rate and potential of each segment for the period 2017-2028.
Follicular Lymphoma Drugs Breakdown Data by Type
Anti-CD20 mAbs
Chemotherapy Agents
Kinase Inhibitor
Others
Follicular Lymphoma Drugs Breakdown Data by Administration Route
Injection
Oral
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Competitive Landscape
This segment focuses on the key players operating in the industry. It underlines all the current and future activities by the prominent manufacturers. By understanding various initiatives being taken up by different players, readers will gain the ability to settle on correct business choices. The authors of the report have provided accurate revenue figures of the companies for the period 2017-2022. The clients are sure to gain the upper hand once they get hold of this report. Key players studied in the research report include:
Roche
Gilead Sciences
TG Therapeutics
Bayer
Secura Bio
Epizyme
Eisai
Acrotech Biopharma
Teva
Eagle Pharmaceuticals
MundiPharma
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Follicular Lymphoma Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Anti-CD20 mAbs
1.2.3 Chemotherapy Agents
1.2.4 Kinase Inhibitor
1.2.5 Others
1.3 Market by Administration Route
1.3.1 Global Follicular Lymphoma Drugs Market Size Growth Rate by Administration Route, 2017 VS 2021 VS 2028
1.3.2 Injection
1.3.3 Oral
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Follicular Lymphoma Drugs Market Perspective (2017-2028)
2.2 Follicular Lymphoma Drugs Growth Trends by Region
2.2.1 Follicular Lymphoma Drugs Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Follicular Lymphoma Drugs Historic Market Size by Region (2017-2022)
2.2.3 Follicular Lymphoma Drugs Forecasted Market Size by Region (2023-2028)
2.3 Follicular Lymphoma Drugs Market Dynamics
2.3.1 Follicular Lymphoma Drugs Industry Trends
2.3.2 Follicular Lymphoma Drugs Market Drivers
2.3.3 Follicular Lymphoma Drugs Market Challenges
2.3.4 Follicular Lymphoma Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Follicular Lymphoma Drugs Players by Revenue
3.1.1 Global Top Follicular Lymphoma Drugs Players by Revenue (2017-2022)
3.1.2 Global Follicular Lymphoma Drugs Revenue Market Share by Players (2017-2022)
3.2 Global Follicular Lymphoma Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Follicular Lymphoma Drugs Revenue
3.4 Global Follicular Lymphoma Drugs Market Concentration Ratio
3.4.1 Global Follicular Lymphoma Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Follicular Lymphoma Drugs Revenue in 2021
3.5 Follicular Lymphoma Drugs Key Players Head office and Area Served
3.6 Key Players Follicular Lymphoma Drugs Product Solution and Service
3.7 Date of Enter into Follicular Lymphoma Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Follicular Lymphoma Drugs Breakdown Data by Type
4.1 Global Follicular Lymphoma Drugs Historic Market Size by Type (2017-2022)
4.2 Global Follicular Lymphoma Drugs Forecasted Market Size by Type (2023-2028)
5 Follicular Lymphoma Drugs Breakdown Data by Administration Route
5.1 Global Follicular Lymphoma Drugs Historic Market Size by Administration Route (2017-2022)
5.2 Global Follicular Lymphoma Drugs Forecasted Market Size by Administration Route (2023-2028)
6 North America
6.1 North America Follicular Lymphoma Drugs Market Size (2017-2028)
6.2 North America Follicular Lymphoma Drugs Market Size by Type
6.2.1 North America Follicular Lymphoma Drugs Market Size by Type (2017-2022)
6.2.2 North America Follicular Lymphoma Drugs Market Size by Type (2023-2028)
6.2.3 North America Follicular Lymphoma Drugs Market Share by Type (2017-2028)
6.3 North America Follicular Lymphoma Drugs Market Size by Administration Route
6.3.1 North America Follicular Lymphoma Drugs Market Size by Administration Route (2017-2022)
6.3.2 North America Follicular Lymphoma Drugs Market Size by Administration Route (2023-2028)
6.3.3 North America Follicular Lymphoma Drugs Market Share by Administration Route (2017-2028)
6.4 North America Follicular Lymphoma Drugs Market Size by Country
6.4.1 North America Follicular Lymphoma Drugs Market Size by Country (2017-2022)
6.4.2 North America Follicular Lymphoma Drugs Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Follicular Lymphoma Drugs Market Size (2017-2028)
7.2 Europe Follicular Lymphoma Drugs Market Size by Type
7.2.1 Europe Follicular Lymphoma Drugs Market Size by Type (2017-2022)
7.2.2 Europe Follicular Lymphoma Drugs Market Size by Type (2023-2028)
7.2.3 Europe Follicular Lymphoma Drugs Market Share by Type (2017-2028)
7.3 Europe Follicular Lymphoma Drugs Market Size by Administration Route
7.3.1 Europe Follicular Lymphoma Drugs Market Size by Administration Route (2017-2022)
7.3.2 Europe Follicular Lymphoma Drugs Market Size by Administration Route (2023-2028)
7.3.3 Europe Follicular Lymphoma Drugs Market Share by Administration Route (2017-2028)
7.4 Europe Follicular Lymphoma Drugs Market Size by Country
7.4.1 Europe Follicular Lymphoma Drugs Market Size by Country (2017-2022)
7.4.2 Europe Follicular Lymphoma Drugs Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Follicular Lymphoma Drugs Market Size (2017-2028)
8.2 Asia-Pacific Follicular Lymphoma Drugs Market Size by Type
8.2.1 Asia-Pacific Follicular Lymphoma Drugs Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Follicular Lymphoma Drugs Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Follicular Lymphoma Drugs Market Share by Type (2017-2028)
8.3 Asia-Pacific Follicular Lymphoma Drugs Market Size by Administration Route
8.3.1 Asia-Pacific Follicular Lymphoma Drugs Market Size by Administration Route (2017-2022)
8.3.2 Asia-Pacific Follicular Lymphoma Drugs Market Size by Administration Route (2023-2028)
8.3.3 Asia-Pacific Follicular Lymphoma Drugs Market Share by Administration Route (2017-2028)
8.4 Asia-Pacific Follicular Lymphoma Drugs Market Size by Region
8.4.1 Asia-Pacific Follicular Lymphoma Drugs Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Follicular Lymphoma Drugs Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Follicular Lymphoma Drugs Market Size (2017-2028)
9.2 Latin America Follicular Lymphoma Drugs Market Size by Type
9.2.1 Latin America Follicular Lymphoma Drugs Market Size by Type (2017-2022)
9.2.2 Latin America Follicular Lymphoma Drugs Market Size by Type (2023-2028)
9.2.3 Latin America Follicular Lymphoma Drugs Market Share by Type (2017-2028)
9.3 Latin America Follicular Lymphoma Drugs Market Size by Administration Route
9.3.1 Latin America Follicular Lymphoma Drugs Market Size by Administration Route (2017-2022)
9.3.2 Latin America Follicular Lymphoma Drugs Market Size by Administration Route (2023-2028)
9.3.3 Latin America Follicular Lymphoma Drugs Market Share by Administration Route (2017-2028)
9.4 Latin America Follicular Lymphoma Drugs Market Size by Country
9.4.1 Latin America Follicular Lymphoma Drugs Market Size by Country (2017-2022)
9.4.2 Latin America Follicular Lymphoma Drugs Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Follicular Lymphoma Drugs Market Size (2017-2028)
10.2 Middle East & Africa Follicular Lymphoma Drugs Market Size by Type
10.2.1 Middle East & Africa Follicular Lymphoma Drugs Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Follicular Lymphoma Drugs Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Follicular Lymphoma Drugs Market Share by Type (2017-2028)
10.3 Middle East & Africa Follicular Lymphoma Drugs Market Size by Administration Route
10.3.1 Middle East & Africa Follicular Lymphoma Drugs Market Size by Administration Route (2017-2022)
10.3.2 Middle East & Africa Follicular Lymphoma Drugs Market Size by Administration Route (2023-2028)
10.3.3 Middle East & Africa Follicular Lymphoma Drugs Market Share by Administration Route (2017-2028)
10.4 Middle East & Africa Follicular Lymphoma Drugs Market Size by Country
10.4.1 Middle East & Africa Follicular Lymphoma Drugs Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Follicular Lymphoma Drugs Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Follicular Lymphoma Drugs Introduction
11.1.4 Roche Revenue in Follicular Lymphoma Drugs Business (2017-2022)
11.1.5 Roche Recent Developments
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Details
11.2.2 Gilead Sciences Business Overview
11.2.3 Gilead Sciences Follicular Lymphoma Drugs Introduction
11.2.4 Gilead Sciences Revenue in Follicular Lymphoma Drugs Business (2017-2022)
11.2.5 Gilead Sciences Recent Developments
11.3 TG Therapeutics
11.3.1 TG Therapeutics Company Details
11.3.2 TG Therapeutics Business Overview
11.3.3 TG Therapeutics Follicular Lymphoma Drugs Introduction
11.3.4 TG Therapeutics Revenue in Follicular Lymphoma Drugs Business (2017-2022)
11.3.5 TG Therapeutics Recent Developments
11.4 Bayer
11.4.1 Bayer Company Details
11.4.2 Bayer Business Overview
11.4.3 Bayer Follicular Lymphoma Drugs Introduction
11.4.4 Bayer Revenue in Follicular Lymphoma Drugs Business (2017-2022)
11.4.5 Bayer Recent Developments
11.5 Secura Bio
11.5.1 Secura Bio Company Details
11.5.2 Secura Bio Business Overview
11.5.3 Secura Bio Follicular Lymphoma Drugs Introduction
11.5.4 Secura Bio Revenue in Follicular Lymphoma Drugs Business (2017-2022)
11.5.5 Secura Bio Recent Developments
11.6 Epizyme
11.6.1 Epizyme Company Details
11.6.2 Epizyme Business Overview
11.6.3 Epizyme Follicular Lymphoma Drugs Introduction
11.6.4 Epizyme Revenue in Follicular Lymphoma Drugs Business (2017-2022)
11.6.5 Epizyme Recent Developments
11.7 Eisai
11.7.1 Eisai Company Details
11.7.2 Eisai Business Overview
11.7.3 Eisai Follicular Lymphoma Drugs Introduction
11.7.4 Eisai Revenue in Follicular Lymphoma Drugs Business (2017-2022)
11.7.5 Eisai Recent Developments
11.8 Acrotech Biopharma
11.8.1 Acrotech Biopharma Company Details
11.8.2 Acrotech Biopharma Business Overview
11.8.3 Acrotech Biopharma Follicular Lymphoma Drugs Introduction
11.8.4 Acrotech Biopharma Revenue in Follicular Lymphoma Drugs Business (2017-2022)
11.8.5 Acrotech Biopharma Recent Developments
11.9 Teva
11.9.1 Teva Company Details
11.9.2 Teva Business Overview
11.9.3 Teva Follicular Lymphoma Drugs Introduction
11.9.4 Teva Revenue in Follicular Lymphoma Drugs Business (2017-2022)
11.9.5 Teva Recent Developments
11.10 Eagle Pharmaceuticals
11.10.1 Eagle Pharmaceuticals Company Details
11.10.2 Eagle Pharmaceuticals Business Overview
11.10.3 Eagle Pharmaceuticals Follicular Lymphoma Drugs Introduction
11.10.4 Eagle Pharmaceuticals Revenue in Follicular Lymphoma Drugs Business (2017-2022)
11.10.5 Eagle Pharmaceuticals Recent Developments
11.11 MundiPharma
11.11.1 MundiPharma Company Details
11.11.2 MundiPharma Business Overview
11.11.3 MundiPharma Follicular Lymphoma Drugs Introduction
11.11.4 MundiPharma Revenue in Follicular Lymphoma Drugs Business (2017-2022)
11.11.5 MundiPharma Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer